Koyfin Home > Directory > Health Care > Amphastar Pharma > Long-term Debt / Equity

Amphastar Pharma Long-term Debt / Equity Chart (AMPH)

Amphastar Pharma annual/quarterly Long-term Debt / Equity from 2014 to 2018.
  • Amphastar Pharma Long-term Debt / Equity for the quarter ending December 12, 2018 was $9m a -38.28% decrease of -3m year over year
  • Amphastar Pharma Long-term Debt / Equity for the last 12 months ending December 12, 2018 was $9m a -38.28% decrease of -3m year over year
  • Amphastar Pharma Annual Long-term Debt / Equity for 2018 was $9m a -37.93% decrease of -3m from 2017
  • Amphastar Pharma Annual Long-term Debt / Equity for 2017 was $12m a 18.84% increase of 2m from 2016
  • Amphastar Pharma Annual Long-term Debt / Equity for 2016 was $10m a -3.87% decrease of 0m from 2015
Other Ratios Metrics:
  • Amphastar Pharma Total Debt / Capital for the quarter ending December 12, 2018 was $12m a -1.34% decrease of 0m year over year
  • Amphastar Pharma Other Liabilities for the quarter ending December 12, 2018 was $10m a -0.42% decrease of 0m year over year
  • Amphastar Pharma Total Debt / Equity for the quarter ending December 12, 2018 was $14m a -1.53% decrease of 0m year over year
View Chart On Koyfin

Quarterly AMPH Long-term Debt / Equity Data

12/2018$9m
09/2018$10m
06/2018$11m
03/2018$12m
12/2017$12m
09/2017$13m
06/2017$12m
03/2017$10m
12/2016$10m
09/2016$10m

Annual AMPH Long-term Debt / Equity Data

2018$9m
2017$12m
2016$10m
2015$10m
2014$13m
2013$4m